Voyager Therapeutics said Novartis would pay $100 million upfront as part of a licensing agreement to develop gene therapy candidates. Voyager would provide Novartis with a licence to develop a preclinical-stage gene therapy candidate for a genetic disorder known as Huntington’s disease (HD).